Generation of a stable activated thrombin activable fibrinolysis inhibitor variant (Q33238932)

24 July 2017

Generation of a stable activated thrombin activable fibrinolysis inhibitor variant (English)

1 reference

24 July 2017

Paul J Declerck

5

0 references

author name string

Erik Ceresa

1

1 reference

24 July 2017

Kirsten Van de Borne

2

1 reference

24 July 2017

Miet Peeters

3

1 reference

24 July 2017

Henri Roger Lijnen

4

1 reference

24 July 2017

Ann Gils

6

1 reference

24 July 2017

language of work or name

English

0 references

publication date

4 April 2006

1 reference

Journal of Biological Chemistry

24 July 2017

1 reference

24 July 2017

281

1 reference

24 July 2017

23

1 reference

24 July 2017

15878-15883

1 reference

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

24 July 2017

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Development of a genotype 325-specific proCPU/TAFI ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha2-macroglobulin and pregnancy zone protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M509839200

21 January 2018

Identifiers

DOI

10.1074/JBC.M509839200

1 reference

24 July 2017

1 reference